All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, August 15, 2022
Home » Blogs » BioWorld MedTech Perspectives » Two nuggets: precious or not?

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Two nuggets: precious or not?

Aug. 21, 2013
By Mark McCarty
No Comments

He's looking for more than just two nuggets
He's sure to be looking for a lot more than just two nuggets.

Sometimes little nuggets of information don’t mean much, but sometimes they mean a lot. It’s not always clear, though, is it? Following are a couple such nuggets, but I’ll let the reader decide what they’re worth.

In a recent congressional hearing, Sen. Patty Murray, said something that surely gave providers a nasty case of the hives. Murray, who chairs the Senate Budget Committee, said at a July 30 hearing that bundled payments “could help incentivize coordination and efficiency” by “creating fixed payments for all the care a patient is expected to need during a period of time.”

I approached the dais after the hearing for clarification (did she really say the “C” word?), but Murray handed me off to a staffer, who promised to get back to me. He e-mailed me as promised, but he didn’t respond when I explained what I was after. He also didn’t respond the following day when I inquired a second time.

There are a lot of people in this town who think capitation is inevitable under accountable care organizations, but it seems as though it’s a bit impolitic to say as much out in the open. It’s a safe bet we haven’t heard the last of this, though.

Devices driving healthcare inflation?

We’ve all heard about statistical cherry picking, but let’s go ahead and dive into the discussion of how medical device spending is driving Medicare spending … or not.

Kavita Patel, MD, of the Brookings Institute appeared at the July 30 Senate hearing mentioned above, and Patel had some interesting numbers to offer. Among these is a table she drew from Medicare data stating that Medicare spending on pharmaceuticals “across the continuum of care” rose from $2.4 billion in 2001 to $63.7 billion a decade later. That’s up by more than a factor of 25.

Meanwhile, spending on durable medical equipment went from $4.5 billion in 2001 to $7.7 billion in 2011, and non-durable medical equipment rose from $1.6 billion to $3.2 billion, again all within the nebulously named “continuum of care.”

I’m not entirely sure what those durable and non-durable categories cover – do they include defibrillators and drug-eluting stents? – but a lot of the numbers I’ve heard about med tech inflation is that it comes in at about 6% a year most years, and routinely accounts for about 6% of total Medicare spending. According to my wizardly arithmetic calculations, 6% annual inflation comes to an increase of about 80% over a decade.

Assuming that’s the case, how can all the policymakers and policy wonks bleat endlessly about medical device spending and not be equally unhinged over a 25-fold increase for inpatient and outpatient drug spending in just 10 years? That’s like losing your cool over a spilled bucket of water while standing in front of a dam that’s about to collapse.

As the picture above reminds us, you can’t always distinguish between gold and iron pyrite until you do a little digging, but there’ll be a lot more where that came from starting next month when Congress returns to Washington for the fiscal 2014 budget talks.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 12, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 12, 2022.
  • Amvuttra

    Alnylam’s Amvuttra rare disease drug among positive recommendations from Europe’s CHMP

    BioWorld
    Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran), a treatment for the rare disease hereditary transthyretin-mediated amyloidosis, was among medicines...
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing